BACKGROUND: Radioresistance represents a major problem in the treatment of head and neck cancer (HNC) patients. To improve response, understanding tumor microenvironmental factors that contribute to radiation resistance is important. Regulatory T cells (Tregs) are enriched in numerous cancers and can dampen the response to radiation by creating an immune-inhibitory microenvironment. The purpose of this study was to investigate mechanisms of Treg modulation by radiation in HNC. METHODS: We utilized an orthotopic mouse model of HNC. Anti-CD25 was used for Treg depletion. Image-guided radiation was delivered to a dose of 10 Gy. Flow cytometry was used to analyze abundance and function of intratumoral immune cells. Enzyme-linked immunosorbent assay was performed to assess secreted factors. For immune-modulating therapies, anti-PD-L1, anti-CTLA-4, and STAT3 antisense oligonucleotide (ASO) were used. All statistical tests were two-sided. RESULTS: Treatment with anti-CD25 and radiation led to tumor eradication (57.1%, n = 4 of 7 mice), enhanced T-cell cytotoxicity compared with RT alone (CD4 effector T cells [Teff]: RT group mean = 5.37 [ 0.58] vs RT + αCD25 group mean =10.71 [0.67], P = .005; CD8 Teff: RT group mean = 9.98 [0.81] vs RT + αCD25 group mean =16.88 [2.49], P = .01) and induced tumor antigen-specific memory response (100.0%, n = 4 mice). In contrast, radiation alone or when combined with anti-CTLA4 did not lead to durable tumor control (0.0%, n = 7 mice). STAT3 inhibition in combination with radiation, but not as a single agent, improved tumor growth delay, decreased Tregs, myeloid-derived suppressor cells, and M2 macrophages and enhanced effector T cells and M1 macrophages. Experiments in nude mice inhibited the benefit of STAT3 ASO and radiation. CONCLUSION: We propose that STAT3 inhibition is a viable and potent therapeutic target against Tregs. Our data support the design of clinical trials integrating STAT3 ASO in the standard of care for cancer patients receiving radiation.
BACKGROUND: Radioresistance represents a major problem in the treatment of head and neck cancer (HNC) patients. To improve response, understanding tumor microenvironmental factors that contribute to radiation resistance is important. Regulatory T cells (Tregs) are enriched in numerous cancers and can dampen the response to radiation by creating an immune-inhibitory microenvironment. The purpose of this study was to investigate mechanisms of Treg modulation by radiation in HNC. METHODS: We utilized an orthotopic mouse model of HNC. Anti-CD25 was used for Treg depletion. Image-guided radiation was delivered to a dose of 10 Gy. Flow cytometry was used to analyze abundance and function of intratumoral immune cells. Enzyme-linked immunosorbent assay was performed to assess secreted factors. For immune-modulating therapies, anti-PD-L1, anti-CTLA-4, and STAT3 antisense oligonucleotide (ASO) were used. All statistical tests were two-sided. RESULTS: Treatment with anti-CD25 and radiation led to tumor eradication (57.1%, n = 4 of 7 mice), enhanced T-cell cytotoxicity compared with RT alone (CD4 effector T cells [Teff]: RT group mean = 5.37 [ 0.58] vs RT + αCD25 group mean =10.71 [0.67], P = .005; CD8 Teff: RT group mean = 9.98 [0.81] vs RT + αCD25 group mean =16.88 [2.49], P = .01) and induced tumor antigen-specific memory response (100.0%, n = 4 mice). In contrast, radiation alone or when combined with anti-CTLA4 did not lead to durable tumor control (0.0%, n = 7 mice). STAT3 inhibition in combination with radiation, but not as a single agent, improved tumor growth delay, decreased Tregs, myeloid-derived suppressor cells, and M2 macrophages and enhanced effector T cells and M1 macrophages. Experiments in nude mice inhibited the benefit of STAT3ASO and radiation. CONCLUSION: We propose that STAT3 inhibition is a viable and potent therapeutic target against Tregs. Our data support the design of clinical trials integrating STAT3ASO in the standard of care for cancerpatients receiving radiation.
Authors: Lena Seifert; Gregor Werba; Shaun Tiwari; Nancy Ngoc Giao Ly; Susanna Nguy; Sara Alothman; Dalia Alqunaibit; Antonina Avanzi; Donnele Daley; Rocky Barilla; Daniel Tippens; Alejandro Torres-Hernandez; Mautin Hundeyin; Vishnu R Mani; Cristina Hajdu; Ilenia Pellicciotta; Philmo Oh; Kevin Du; George Miller Journal: Gastroenterology Date: 2016-03-03 Impact factor: 22.682
Authors: David Hong; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes; John Nemunaitis; Nathan Fowler; Tianyuan Zhou; Joanna Schmidt; Minji Jo; Samantha J Lee; Mason Yamashita; Steven G Hughes; Luis Fayad; Sarina Piha-Paul; Murali V P Nadella; Morvarid Mohseni; Deborah Lawson; Corinne Reimer; David C Blakey; Xiaokun Xiao; Jeff Hsu; Alexey Revenko; Brett P Monia; A Robert MacLeod Journal: Sci Transl Med Date: 2015-11-18 Impact factor: 17.956
Authors: Matthew J Reilley; Patricia McCoon; Carl Cook; Paul Lyne; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes; John Nemunaitis; Nathan Fowler; Michael Curran; Qinying Liu; Tianyuan Zhou; Joanna Schmidt; Minji Jo; Samantha J Lee; Mason Yamashita; Steven G Hughes; Luis Fayad; Sarina Piha-Paul; Murali V P Nadella; Xiaokun Xiao; Jeff Hsu; Alexey Revenko; Brett P Monia; A Robert MacLeod; David S Hong Journal: J Immunother Cancer Date: 2018-11-16 Impact factor: 13.751
Authors: Ana Teresa Pinto; Marta Laranjeiro Pinto; Ana Patrícia Cardoso; Cátia Monteiro; Marta Teixeira Pinto; André Filipe Maia; Patrícia Castro; Rita Figueira; Armanda Monteiro; Margarida Marques; Marc Mareel; Susana Gomes Dos Santos; Raquel Seruca; Mário Adolfo Barbosa; Sónia Rocha; Maria José Oliveira Journal: Sci Rep Date: 2016-01-06 Impact factor: 4.379
Authors: Thomas E Bickett; Michael Knitz; Laurel B Darragh; Shilpa Bhatia; Benjamin Van Court; Jacob Gadwa; Shiv Bhuvane; Miles Piper; Diemmy Nguyen; Hua Tu; Laurel Lenz; Eric T Clambey; Kevin Barry; Sana D Karam Journal: Clin Cancer Res Date: 2021-09-13 Impact factor: 12.531
Authors: Thomas E Bickett; Michael W Knitz; Miles Piper; Ayman J Oweida; Jacob Gadwa; Laurel B Darragh; Diemmy Nguyen; Shilpa Bhatia; Shiv Bhuvane; Andy V Phan; Benjamin Van Court; Sophia Corbo; Tiffany Pham; Alexander L Dent; Laurel Lenz; Sana D Karam Journal: Mol Ther Date: 2021-11-15 Impact factor: 11.454
Authors: Jun Wei; Peiwen Chen; Pravesh Gupta; Martina Ott; Daniel Zamler; Cynthia Kassab; Krishna P Bhat; Michael A Curran; John F de Groot; Amy B Heimberger Journal: Neuro Oncol Date: 2020-02-20 Impact factor: 12.300
Authors: Li Pan; Ruijie Zhang; Ling Ma; Christopher R Pierson; Jonathan L Finlay; Chenglong Li; Jiayuh Lin Journal: Cancer Biol Ther Date: 2021-07-13 Impact factor: 4.875